NRX Pharmaceuticals (NRXP) Current Assets (2017 - 2026)

NRX Pharmaceuticals (NRXP) has reported Current Assets for 10 consecutive years, with $29.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Assets rose 535.25% year-over-year to $29.2 million in Q2 2026; TTM through Jun 2026 was $29.2 million, a 535.25% increase from a year earlier, with the FY2025 full-year figure at $8.9 million, up 169.29% from the prior year.
• Current Assets was $29.2 million for Q2 2026 at NRX Pharmaceuticals, up from $7.4 million in the prior quarter.
• Over five years, Current Assets peaked at $43.6 million in Q1 2022 and troughed at $3.3 million in Q4 2024.
• A 5-year average of $15.2 million and a median of $10.4 million in 2025 frame the typical range for Current Assets.
• Across the five-year window, Current Assets soared 72875.69% in 2022 and tumbled 84.62% in 2024, its largest moves.
• Over 5 years, Current Assets stood at $25.8 million in 2022, then plunged by 73.31% to $6.9 million in 2023, then sank by 52.03% to $3.3 million in 2024, then surged by 169.29% to $8.9 million in 2025, then jumped by 227.91% to $29.2 million in 2026.
• The last three Current Assets figures came in at $29.2 million (Q2 2026), $7.4 million (Q1 2026), and $8.9 million (Q4 2025), per Business Quant data.